Statin users have lower fatty acid oxidative metabolisms in muscle mitochondria and have a higher content of long-chain and medium-chain acylcarnitines in muscles.

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Eva Bolsteina

Paul Stradins Clinical University Hospital, Riga (Latvia)

9 More presentations in this session

Presentation thumbnail

Discussant - Dyslipidaemias: current strategies and innovations

Presentation thumbnail

The efficacy and safety of low-intensity statins for high bleeding risk patients after PCI in Asian populations

Doctor Z. Zhang (Tianjin, CN)

Abstract Slides Video

Presentation thumbnail

The efficacy of tafolecimab in lipoprotein(a) reductions in hypercholesterolaemic patients: a pooled analysis of three phase 3 trials

Ms H. Shen (Beijing, CN)

Abstract Slides Video

Presentation thumbnail

Efficacy and metabolic impact of combination therapy vs. high-intensity statin monotherapy: an exploratory analysis of the Save SAMS Trial

Professor S. Hong (Seoul, KR)

Abstract Slides Video

Presentation thumbnail

VICTORION-Mono China: efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated LDL-C

Doctor X. Liu (CH)

Access the full session

Session thumbnail

New perspectives in cardiology (1) - Dyslipidaemias: current strategies and innovations

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Lipid control in cardiovascular patients

Congress Presentation

What’s new in LDL lowering?

Congress Presentation

Stepwise approach to lipid-lowering therapies: which one, when, and for whom?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources